SynthesisBMC cancer2021
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Synthesis in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06663098 (Continued PD-L1 Inhibition With Atezolizumab With Rechallenge Chemotherapy in Patients With Sensitive Relapse SCLC Progressing on First-line Platinum-etoposide Chemotherapy and a PD-L1 Inhibitor), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continued PD-L1 Inhibition With Atezolizumab With Rechallenge Chemotherapy in Patients With Sensitive Relapse SCLC Progressing on First-line Platinum-etoposide Chemotherapy and a PD-L1 Inhibitor: CARRY-ON Study-GOIRC-01-2023
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.PharmacoEconomics · 2022Pooled it
- Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study.Cancer research communications · 2025Trial
- End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center.BMC cancer · 2026Article
- Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study.Chinese medical journal · 2025Article
- A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.Breast cancer research : BCR · 2025Article
- Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.Frontiers in immunology · 2025Review
- Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.Frontiers in pharmacology · 2025Article
- Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.Frontiers in immunology · 2025Observational
- Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.Journal for immunotherapy of cancer · 2024Review
- Article
- Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.Cancer research communications · 2023Article
- Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.Cancer cell · 2023Article
- Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.Biomedicines · 2023Article
- Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancer.CPT: pharmacometrics & systems pharmacology · 2023Article
- Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.Cancer immunology, immunotherapy : CII · 2022Article
- Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.Frontiers in pharmacology · 2022Article
- Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyond progression in patients receiving an anti-PD-1/PD-L1 based regimen for an advanced solid tumor.
methodsA systematic literature search was performed to identify prospective clinical trials reporting data on overall response rate by immune-related criteria and/or the number of patients treated beyond conventional criteria-defined PD and/or the number of patients achieving a clinical benefit after an initial PD with regimens including an anti-PD-1/PD-L1 agent which received the FDA approval for the treatment of an advanced solid tumor.
results254 (4.6%) responses after an initial RECIST-defined progressive disease were observed among 5588 patients, based on 35 trials included in our analysis reporting this information. The overall rate of patients receiving treatment beyond progressive disease was 30.2%, based on data on 5334 patients enrolled in 36 trials, and the rate of patients who achieved an unconventional response among those treated beyond progressive disease was 19.7% (based on 25 trials for a total of 853 patients).
conclusionThe results of our systematic review support the clinical relevance of unconventional responses to anti-PD-1/PD-L1-based regimens; however, most publications provided only partial information regarding immune-related clinical activity, or did not provide any information at all, highlighting the need of a more comprehensive report of such data in trials investigating immunotherapy for the treatment of patients with advanced tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.